Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan Intervention Study in ADPKD Patients Without PKD1/PKD2 Mutations (TIAG)
jRCTs031180259Completed
- Sponsor
- Dojindo Laboratories
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Dojindo Laboratories. Primary endpoint: Increase rate of total kidney volume. Started Apr 2019; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCTs031180259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180259.